On June 22, Lakewood-Amedex turned every ten of its shares into one. By November, that move had become the reason Nasdaq would not give the company a compliance period.
Nasdaq's listing team sent a delisting notice on November 10, applying a rule that bars the standard compliance period for any company that has done a reverse split within the prior year. Lakewood-Amedex had done one that June. The stock had been below $1.00 for 30 consecutive business days — September 29 through November 9 — before the notice arrived.
That compliance period normally gives a company time to bring its price back above the minimum before trading is suspended. Here, the reverse split within the prior year had closed that path. Without a hearing request by November 17, trading was set to be suspended at the open of November 19.
Shares closed 15.03% higher at $0.2449, on dollar volume of about $14.8 million.
The company says it intends to request a hearing before a Nasdaq panel, which would pause the suspension while the panel reviews its case. At the hearing, it plans to present a plan to regain compliance — one the filing says may include a reverse split.
The filing says there is no assurance the panel will grant continued listing or that the company will regain compliance.